This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclearmedicine diagnostic procedures.
F-18 fluoroestradiol (FES)-PET scans can predict whether or not endocrine therapy may be effective in women with estrogen receptor (ER)-positive breast cancer, according to a study published March 13 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine. A visual abstract of the analysis.
The document was published jointly March 11 in the Journal of Nuclear Cardiology , Clinical Infectious Diseases , the Heart Rhythm Journal , and JACC: Cardiovascular Imaging. The recommendations emphasize the complementary nature of these advanced nuclearmedicine exams.
However, mpMRI misses about 10% of cases, typically in patients with lower-grade disease and in patients with cribriform pattern disease, a subtype much more likely to recur after surgery or radiation therapy, he noted. It also includes a well-established grading system that accurately correlates with histopathology.
Preliminary studies suggest the tracer may also be effective in patients with earlier, more treatable stages of the disease, yet most of these studies have been retrospective and subject to a large risk of bias, the authors noted.
PET imaging using a newly developed radiotracer has identified different patterns of brain tau pathology over time in early-onset versus late-onset Alzheimer’s disease patients, according to a study published February 1 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
The study was published February 13 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine. Triple-negative breast cancer (TNBC) accounts for up to 20% of breast cancer cases and is one of the most aggressive subtypes, with a five-year survival rate of approximately 40%.
TORONTO -- AuntMinnie.com spoke with prostate cancer imaging expert Phillip Kuo, MD, PhD, of the City of Hope in Duarte, CA, at the Society of NuclearMedicine and Molecular Imaging annual meeting about new developments in PET/CT imaging in patients on Lu-177 PSMA-617 therapy. last year for Alzheimer's disease.
Patients with less tau pathology on PET scans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Research suggests that the accumulation of these proteins is a continuous process that starts decades before the onset of symptoms.
Currently, the CMS bundles Medicare payments for PET radiotracers for diagnosing disease as part of the packaged cost of imaging procedures in hospital outpatient settings. Mo-99 is the source material for Tc-99m, which is used in an estimated 40,000 nuclearmedicine diagnostic exams each day in the U.S.
PET brain scans show persistent brain inflammation in patients with multiple sclerosis (MS), despite being treated with high-efficacy disease-modifying therapies, according to a recent study by researchers in Boston. Image courtesy of Clinical NuclearMedicine.
Centers for Medicare and Medicaid Services (CMS) announced on October 13 that it has lifted its coverage limit of one beta-amyloid PET scan per lifetime for patients with Alzheimer’s disease. The decision was applauded by national associations, many of which expressed support for the action during the comment period.
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclearmedicine, diagnostic radiology, and radiation oncology.
PET/CT imaging using gallium-68 (Ga-68) Fibroblast activation protein inhibitor (FAPI) radiotracer over F-18 FDG appears promising in women with invasive lobular carcinoma (ILC), according to a study published March 14 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
The Society of NuclearMedicine and Molecular Imaging (SNMMI) has bestowed its Georg Charles de Hevesy Nuclear Pioneer award on Carolyn Anderson, PhD, of the University of Missouri-Columbia (MU). The award honors those who have made outstanding contributions in the field of nuclearmedicine, the SNMMI said.
Targeting the HER2 protein, which is commonly expressed in ovarian cancer, the therapy (anti-HER2 225Ac-PRIT) is a potential treatment for the otherwise incurable disease. This research was published in the Journal of NuclearMedicine.
Theranostics pairs diagnostic biomarkers that can be visualized on nuclearmedicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.
New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC), according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
His research interests include using structural and functional MRI -- particularly ultrahigh-field, 7-tesla MRI -- to map brain microstructure and develop neurosurgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia. Dmitry Beyder.
A PET radiotracer for diagnosing Alzheimer’s disease may also be used to measure vascular brain changes in patients during PET/MRI scans, according to a study published December 7 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy (RPT) with Pluvicto for advanced prostate cancer, according to a study published August 8 in the Journal of NuclearMedicine. Yet whether SPECT/CT can be used to determine disease progression or response has yet to be delineated, they noted.
An emerging radioligand therapy could be particularly effective for controlling advanced sarcoma compared to other cancers, according to research presented June 8 in a Young Investigator Award session at the Society of NuclearMedicine and Molecular Imaging (SNMMI) meeting in Toronto. Image courtesy of SNMMI.
Urbain, MD, PhD, FASNC , professor of radiology/nuclearmedicine and medicine, vice chair of theranostics, and director of nuclearmedicine at Roswell Park Cancer Center at the University of Buffalo , Buffalo, New York. and ‘How can we ensure diversity in all parts of the nuclearmedicine family?’
An AI algorithm designed for brain PET imaging found a glioblastoma in a patient that had gone undetected by physicians, according to a case reported February 15 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
TORONTO -- AuntMinnie.com spoke with cardiac PET imaging expert Krishna Patel, MD, from Mount Sinai in New York City, at the Society of NuclearMedicine and Molecular Imaging annual meeting.
PET/CT imaging with F-18 sodium fluoride (NaF) is emerging as a sensitive tool for detecting early atherosclerosis, according to a presentation at the recent Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
An emerging PET/CT radiotracer may be more predictive of progressive pulmonary fibrosis in interstitial lung patients than F-18 FDG PET/CT, according to research presented June 8 at the 2024 Society of NuclearMedicine and Molecular Imaging Annual Meeting (SNMMI).
A new PET radiotracer has the potential for visualizing responses in liver cancer patients undergoing immunotherapy, according to a study published December 12 in the Journal of NuclearMedicine. Image courtesy of the Journal of NuclearMedicine.
“Skin biopsy is the gold standard for diagnosing calciphylaxis, but it can worsen lesions and confer poorer disease prognosis,” the researchers wrote, in a study published October 23 in JAAD International. All but one patient had renal disease and most had several other comorbidities, the authors wrote.
Thomas Hope, MD, a radiologist and nuclearmedicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added.
PET/MRI scans have revealed immune system reactions after COVID-19 vaccines in children with cancer, according to a study published October 26 in the Journal of NuclearMedicine. Several studies have demonstrated that vaccine-related lymphadenopathy may confound disease assessment in oncology patients, the researchers added.
Up to 80% of women with the disease who respond to first-line chemotherapy relapse within 18 months, the authors explained. Two experienced nuclearmedicine physicians evaluated the images and calculated total lesion glycolysis and metabolic tumor volume parameters in regions of interest based on tumor uptake of F-18 FDG radiotracer.
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of NuclearMedicine. FAPI-PET either confirmed or ruled out the disease in all cases, the group found.
Middlebrooks' research interest consists of using ultrahigh-field, 7-tesla MRI to plot brain microstructure and develop surgical treatment of brain tumors, epilepsy, and neurodegenerative and movement disorders such as Parkinson's disease, essential tremor, and dystonia.
This is just the third year that RSNA has offered a dedicated track on nuclearmedicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. 9:30 a.m. |
Moreover, the approach could help detect disease that other effective prostate cancer PET radiotracers may miss, said Heying Duan, MD, a nuclearmedicine research scientist at Stanford University, during a November 26 scientific session. You've hear a lot about PSMA.
Imaging more broadly offers significant value to patients, providers, and health care systems when used appropriately through disease prevention, detection, diagnosis, prognosis, and in the delivery and monitoring of precise, minimally invasive treatment," the group explained. Nuclearmedicine 0.76 million Medicaid patients.
A recently developed PET radiotracer identified sources of pain in patients with complex regional pain syndrome (CRPS) and led to effective treatments, according to a study presented June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting.
The primary outcome was the correct identification of the prostate cancer tumor stage, which is crucial for surgeons to determine the extent of the disease -- whether it has spread beyond the prostate gland, for instance. Out of 150 men who participated, 134 ultimately underwent radical prostatectomies (the mean age was 62 years old).
Katherine Zukotynski, MD, PhD, of McMaster University in Hamilton, Ontario, has been awarded the American College of NuclearMedicines (ACNM) 2025 Lifetime Achievement Award. Her main areas of research are in PET/CT applications in oncology, neurodegenerative disease, and machine learning,McMastersaid.
Nuclearmedicine technology firm Positrigo of Zurich, Switzerland, has secured European market clearance for its dedicated brain PET system, NeuroLF. The company received U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content